see list of all thrombolytic trials in CVA for more details
Benefits:
12% absolute risk reduction benefit (NNT = 8-9) at 3 months
Lower percentage of patients who left hospital severely disabled
Comparable 3-month mortality rate (even with increased rate of ICH)
Risks:
1% increase in mortality
5% increase in nonfatal intracranial hemorrhage
Confirmed NINDS findings even when therapeutic window extended to 4.5hr
As a result AHA/ASA now recommends tPA for patients presenting up to 4.5hr after symptom onset
Thrombolytics for acute ischemic stroke
Thrombolytics for STEMI
Thrombolytics for pulmonary embolism
Anti-platelet agent reversal
Antiplatelet medications
Dabigatran reversal
Cardiovascular antibiotics
Low molecular weight heparin